{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:15:26Z","timestamp":1792790126049,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12325-022-02069-6","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T16:05:32Z","timestamp":1647273932000},"page":"2085-2095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-7287","authenticated-orcid":false,"given":"Atsuya","family":"Miki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuyo","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LESPOIR Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"10","key":"2069_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske M, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: result from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2069_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"M Leske","year":"2003","unstructured":"Leske M, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48\u201356.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2069_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128(1):71-p150.","journal-title":"Ophthalmology"},{"issue":"6","key":"2069_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open glaucoma. Arch Ophthalmol. 2002;120(6):701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"2069_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.survophthal.2019.09.004","volume":"65","author":"K Mansouri","year":"2020","unstructured":"Mansouri K, Tanna AP, DeMoraes CG, et al. Review of the measurement and management of 24-hour intraocular pressure in patients with glaucoma. Surv Ophthalmol. 2020;65:171\u201386.","journal-title":"Surv Ophthalmol"},{"key":"2069_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","volume":"220","author":"M Aihara","year":"2020","unstructured":"Aihara M, Lu F, Kawata H, et al. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase\u00a03 AYAME study. Am J Ophthalmol. 2020;220:53\u201363.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2069_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","volume":"64","author":"M Aihara","year":"2020","unstructured":"Aihara M, Ropo A, Lu F, et al. Intraocular-pressure lowering effect of omidenepag isopropyl in latanoprost non-\/low-responder patients with primary open-glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64(4):398\u2013406.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"2069_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M, Lu F, Kawata H, et al. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. JPN J Ophthalmol. 2021;65(6):810\u20139.","journal-title":"JPN J Ophthalmol"},{"key":"2069_CR9","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/OPTH.S271789","volume":"14","author":"K Inoue","year":"2020","unstructured":"Inoue K, Inoue J, Kunimatsu-Sanuki S, et al. Short-term efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Clin Ophthalmol. 2020;14:2943\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"2069_CR10","doi-asserted-by":"publisher","first-page":"e040301","DOI":"10.1136\/bmjopen-2020-040301","volume":"11","author":"S Nakakura","year":"2021","unstructured":"Nakakura S, Kanamori A, Fukuma Y, et al. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study. BMJ Open. 2021;11(1):e040301.","journal-title":"BMJ Open"},{"issue":"4","key":"2069_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/17469899.2021.1935241","volume":"16","author":"M Aihara","year":"2021","unstructured":"Aihara M, Aung T, Bacharach J, et al. Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update. Expert Rev Ophthalmol. 2021;16(4):243\u201350.","journal-title":"Expert Rev Ophthalmol"},{"issue":"5","key":"2069_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10384-021-00855-3","volume":"65","author":"R Sakata","year":"2021","unstructured":"Sakata R, Fujishiro T, Saito H, et al. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Jpn J Ophthalmol. 2021;65(5):591\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"2069_CR13","first-page":"e10064","volume":"12","author":"S Oogi","year":"2020","unstructured":"Oogi S, Nakakura S, Terao E, et al. One year follow up study of change in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2\u03b1 to omidenepag isopropyl. Cureus. 2020;12(8):e10064.","journal-title":"Cureus"},{"issue":"21","key":"2069_CR14","first-page":"4879","volume":"171","author":"K Omori","year":"2014","unstructured":"Omori K, Kida T, Hori M, Ozaki H, Murata T. Multiple role of the PGE2-EP receptor signal in vascular permeability. Br J Ophthalmol. 2014;171(21):4879\u201389.","journal-title":"Br J Ophthalmol"},{"issue":"2\u20133","key":"2069_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.plefa.2013.04.004","volume":"89","author":"I Gomez","year":"2013","unstructured":"Gomez I, Foudi N, Longrois D, Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids. 2013;89(2\u20133):55\u201363.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"4","key":"2069_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jop.2020.0071","volume":"37","author":"M Fuwa","year":"2021","unstructured":"Fuwa M, Shimazaki A, Odani-Kawabata N, et al. Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys. J Ocul Pharmacol Ther. 2021;37(4):223\u20139.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02069-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:21:39Z","timestamp":1651303299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02069-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02069-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}